TITLE

NexMed Completes Study on Topical Impotence Treatment

PUB. DATE
October 1999
SOURCE
Worldwide Biotech;Oct99, Vol. 11 Issue 10, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the announcement of NexMed Inc. on the evaluation of its proprietary alprostadil cream for treating male erectile dysfunction (MED) in a multiple-use clinical study in China that involved patients afflicted with MED. Results of the clinical study; Comments from Doctor Y. Joseph Mo, president and chief executive officer of Nexmed; Examples of NexMed's line of products.
ACCESSION #
2330924

 

Related Articles

  • Great Expectations in the Pipeline. P., Shankar // njbiz;12/10/2007, Vol. 20 Issue 51, p1 

    The article focuses on upcoming drug products from NexMed, a pharmaceutical firm in East Windsor, New Jersey. The topically applied drug, known internally as NexMed's E.D. product, for erectile dysfunction, targets men who, for reasons that include side effects, cannot use any of the top three...

  • NexMed Retains FTN to Weigh Alternatives. Marino, Jonathan // Mergers & Acquisitions Report;4/20/2009, Vol. 22 Issue 16, p2 

    The article reports on the retention of FTN Equity Capital Markets Corp. by transdermal products technology developer NexMed Inc. as a financial advisor to assist with its consideration of strategic alternatives, including a possible sale, in April 2009. The company is considering various...

  • Feds Put the Brakes On NexMed Cream. Gaudio, Thomas // njbiz;7/28/2008, Vol. 21 Issue 31, p2 

    The article reports on the non-approval of the NexMed Cream by the U.S. Food and Drug Administration (FDA) because it could cause cancer at high doses in some mice. Vivian Liu, chief executive officer of NexMed, said that the genetically engineered mice they used is no longer an accepted animal...

  • NexMed reports net loss for second quarter.  // Biotech Financial Reports;Oct99, p4 

    Reports on Robbinsville, New Jersey-based NexMed Inc.'s announcement of its revenue for the quarter ended June 30, 1999. Total net loss; Total sale from its joint venture operations in China; Information on the company.

  • NexMed garners Japanese patent.  // Medical Device Daily;6/28/2010, Vol. 14 Issue 123, p7 

    The article reports on the decision of Japan's Patent Office to approve NexMed's patent "Prostaglandin Composition for the Treatment of Male Erectile Dysfunction."

  • NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.  // Biotech Business;Sep2003, Vol. 16 Issue 9, p4 

    Reports the progress in the topical treatment for premature ejaculation development project of NexMed Inc., a developer of innovative transdermal treatments based on its NexACT proprietary drug delivery technology.

  • INVEST NEW JERSEY. McKnight, Marshall // Business News New Jersey;12/05/2000, Vol. 13 Issue 49, p16 

    Focuses on the increased stock prices of New Jersey-based NexMed Inc. Growth of stock value following the completion of the Phase III of the company's Befar erectile dysfunction cream.

  • More help on the way.  // Business News New Jersey;05/25/98, Vol. 11 Issue 21, p3 

    Reports on PT-14, a drug used for diagnosis and treatment of male erectile dysfunction.

  • New treatments for impotence.  // FDA Consumer;Dec85/Jan86, Vol. 19 Issue 10, p12 

    An estimated 10 million American males suffer from impotence. Researchers have found that about half the cases are due to physical, rather than psychological problems. Whatever the cause, most cases can now be successfully treated.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics